Evolving to the next phase of viral therapy development
UK-based Theolytics is about to begin the first clinical trials for one of its cancer-fighting viruses. It’s a major step for any biotech company, often reached only after years of adjusting and readjusting in both the lab and the boardroom. Successful growth requires adaptation, and Theolytics CEO/Co-Founder Charlotte Casebourne Stock knows all ab ...